The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1444923
This article is part of the Research Topic Community Series in Post-Translational Modifications of Proteins in Cancer Immunity and Immunotherapy, Volume III View all 4 articles
The modification role and tumor association with a methyltransferase: KMT2C
Provisionally accepted- Xinxiang Medical University, Xinxiang, China
Histone methylation can affect chromosome structure and binding to other proteins, depending on the type of amino acid being modified and the number of methyl groups added, this modification may promote transcription of genes (H3K4me2, H3K4me3, and H3K79me3) or reduce transcription of genes (H3K9me2, H3K9me3, H3K27me2, H3K27me3, and H4K20me3). In addition, advances in tumor immunotherapy have shown that histone methylation as a type of protein post-translational modification is also involved in the proliferation, activation and metabolic reprogramming of immune cells in the tumor microenvironment. These post-translational modifications of proteins play a crucial role in regulating immune escape from tumors and immunotherapy. Lysine methyltransferases are important components of the posttranslational histone methylation modification pathway. Lysine methyltransferase 2C (KMT2C), also known as MLL3, is a member of the lysine methyltransferase family, which mediates the methylation modification of histone 3 lysine 4 (H3K4), participates in the methylation of many histone proteins, and regulates a number of signaling pathways such as EMT, p53, Myc, DNA damage repair and other pathways.Studies of KMT2C have found that it is aberrantly expressed in many diseases, mainly tumors and hematological disorders. It can also inhibit the onset and progression of these diseases. Therefore, KMT2C may serve as a promising target for tumor immunotherapy for certain diseases. Here, we provide an overview of the structure of KMT2C, disease mechanisms, and diseases associated with KMT2C, and discuss related challenges.
Keywords: Histone Methylation, Kmt2c, Biological process, Cancer, Immunotherapy
Received: 06 Jun 2024; Accepted: 22 Jul 2024.
Copyright: © 2024 Jiao, Lv, Liu, Liu, Han, Xiong, Zhou, Zhong, Kang and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yunjuan Jiao, Xinxiang Medical University, Xinxiang, China
Mingjie Liu, Xinxiang Medical University, Xinxiang, China
Yun Liu, Xinxiang Medical University, Xinxiang, China
Miaomiao Han, Xinxiang Medical University, Xinxiang, China
Xiwen Xiong, Xinxiang Medical University, Xinxiang, China
Hongyan Zhou, Xinxiang Medical University, Xinxiang, China
Jiateng Zhong, Xinxiang Medical University, Xinxiang, China
Xiaohong Kang, Xinxiang Medical University, Xinxiang, China
Wei Su, Xinxiang Medical University, Xinxiang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.